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OUTLINE OF THE THESIS  
In Chapter I, the rational for this study will be presented focusing the need for identification 
of predictive/prognostic biomarkers of persistent HPV infection. Additionally, the aims of this 
thesis will also be described in this chapter.   
In Chapter II, it will be presented a review of literature which will briefly explain the 
potential impact of microRNAs as biomarkers of HPV-associated carcinogenesis, with a 
major focus on the potential of miR-125b and miR-34a. This chapter is presented as the 
following article: 
Ribeiro J, Sousa H. ROLE OF MICRORNAS IN CERVICAL CANCER: ARE MIR-
125B AND MIR-34A GOOD ENOUGH?  Cancer Letters (submitted) 
In Chapter III, it will be characterized the profile of HPV-genotypes in women from the 
northern region of Portugal with major focus on the characterization of HPV16 infection and 
HPV16 physical status. This chapter is presented as the following article: 
Ribeiro J, Teixeira D, Dias J, Monteiro P,
 
Loureiro J, Baldaque I, Medeiros R, Sousa 
H. MOLECULAR CHARACTERIZATION OF HPV GENOTYPES IN PORTUGUESE 
WOMEN AND CONTRIBUTES FOR FUTURE APPROACHES. Journal of Medical 
Virology (submitted). 
In Chapter IV, it will be shown the results of miR-125b and miR-34a expression in different 
cervical lesions, including carcinomas, discussing its utility as predictive/prognostic 
biomarkers of HPV infection and cervical cancer development. This chapter is presented as 
the following article: 
OUTLINE OF THE THESIS 
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Ribeiro J, Dias J, Monteiro P,
 
Loureiro J, Baldaque I, Medeiros R, Sousa H. miR-34a 
AND miR-125b EXPRESSION IN HPV INFECTION AND CERVICAL CANCER 
DEVELOPMENT. BMC Cancer (submitted). 
In Chapter V, it will be summarized the importance of the results obtained in this thesis. Up 
to our knowledge, this is the first study to evaluate the expression of miR-34a and miR-125b 
in cervical tissues as predicte/prognostic markers of HPV infection outcome. Additionally, it 
will be suggested future directions for research in this field of knowledge.  
Finally, in Chapter VI, it will be presented the references of the thesis.  
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ABSTRACT 
 
Cervical cancer constitutes a serious public health issue representing the third most 
commonly diagnosed cancer in females with approximately 530 000 of new cancer cases 
each year and a total of 275 100 deaths among females in 2008. In Portugal cervical cancer 
is the 4th most frequent cancer in with 950 new diagnosis and 378 deaths per year. 
 
Persistent infection with one or more carcinogenic types of human papillomavirus (HPV) 
has been established as the main etiological factor of squamous intraepithelial lesions of the 
cervix which may progress to high-grade dysplasia or to invasive carcinoma. The majority 
of HPV infections are asymptomatic and the outcome of HPV infection is variable. Despite 
recent advances, clinicians still demand for the identification of useful biomarkers of 
prognosis of HPV infection and progression of lesions. 
This study was performed with exfoliated cervical cells collected from women with different 
cervical lesions and cancer. Firstly, we aimed to characterize HPV genotypes in our 
population. Our results showed that HPV16 is the most frequent types among type followed 
by HPV31, 58, 39, 53 and 66. Surprising, HPV18 proved to be a rare genotype in our 
population. Physical status of HPV’s genome has been described as potential prognostic 
marker and therefore we determined the viral physical status in HPV16 positive cases. 
Results showed that it was possible to detect integrated forms in early lesions of the cervix. 
Another aim consist in to analyze the expression of two miRNAs (miR-125b and miR-34a) 
in cervical cancer tissues and to evaluate its impact as predictive/prognostic biomarkers of 
lesions and cancer of the cervix.  
Regarding results obtained to miR125b expression, we observed a two-fold increased levels 
of miR-125b among normal cases with HPV infection. Moreover, data showed a gradually 
trend to down-regulation of miR-25b expression with lesions progression, becoming a 
significant decreased expression in women with carcinoma. In contrast to previous reports, 
miR-34a expression was found increased among women with normal cervix and HPV 
infection however, when comparing LSIL, HSIL or CIS/ICC with reference group we 
observe no significant differences in relative expression. This study revealed that levels of 
miR-34a remain constant among different cervical lesions and cancer tissues and results 
regarding miR-125b expression suggest that miR-125b could probably be used as useful tool 
for cervical lesions diagnosis/prognosis. 
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RESUMO 
 
O cancro do colo do útero assume-se como um sério problema de saúde pública, 
representando a terceira neoplasia ginecológica mais frequente em todo o mundo com cerca 
de 530 000 casos diagnosticados por ano. Em Portugal, o são registados cerca de 950 novos 
casos e 378 mortes por ano tornando-se a 4ª neoplasia mais frequente no país.  
A infecção persistente com um ou mais tipos de Human papillomavirus (HPV) de alto risco 
foi estabelecida como o principal fator etiológico de lesões intra-epiteliais do colo do útero 
que podem evoluir para lesões de alto grau ou carcinoma invasivo. A maioria das infecções 
por HPV são assintomáticas, contudo o resultado da infeção por HPV é variável. Apesar dos 
avanços recentes, os clínicos exigem cada vez mais a necessidade de identificar 
biomarcadores uteis na definição do prognóstico da infeção por HPV.  
Este estudo foi realizado usando raspagens do colo do útero de mulher com diferentes lesões, 
incluindo carcinomas do colo do útero. O primeiro objetivo foi caracterizar a infeção por HPV 
na população em estudo. Os resultados mostram que o HPV16 é o genótipo mais frequente 
seguido pelo HPV31, 58, 39, 53 e 66. Notavelmente, o HPV18 mostrou ser um genótipo raro 
entre a nossa população. O estado físico do genoma viral tem sido descrito como um potencial 
biomarcador de prognóstico, nesse sentido, foi verificado o estado de integração dos casos 
HPV16 positivos. Os resultados obtidos mostraram que é possível encontrar formas 
integradas em lesões de baixo grau, destacando o facto que a integração viral pode ser um 
evento precoce no processo de carcinogenese. No entanto, mais estudos  
Outro objetivo consistia em estudar os níveis de expressão de dois miRNAs (miR-125b e 
miR-34a) em células do colo do útero e avaliar o seu potencial como biomarcadores de lesões 
e cancro. Considerando os resultados de expressão do miR-125b, obteve-se um aumento 
significativo da expressão em raspagens com citologia normal HPV positivas. Além disso, os 
resultados mostraram uma tendência para a diminuição gradual da expressão do miR-125b ao 
logo da progressão das lesões. Nos carcinomas a expressão do miR-125b encontra-se 
substancialmente diminuída. Em contraste com informação descrita previamente, o miR-34a 
encontra-se aumentado nos casos normais HPV positivos, no entanto, nos casos com lesões de 
baixo, alto grau e carcinomas não se verificaram diferenças estatisticamente significativas nos 
níveis do miR-34a. Em suma, os nossos dados revelaram que a expressão do miR-34a 
mantem-se contante entre as diferentes lesões/cancro do colo uterino, enquanto que expressão 
do miR-125b encontra-se alterada sugerindo a possibilidade do miR-125b ser um bom 
marcador preditivo para lesões do colo do útero e infeção por HPV. 
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BACKGROUND  
Cancer is a major health problem worldwide, being one of the major death causes even in developed 
countries. Currently, cervical cancer is the third most common cancer among women and it represents 
a severe threat to women´s live. Data from World Health Organization (WHO) showed that there were 
590 000 new cases of cervical cancer and over 275 000 deaths in 2008 with huge differences in 
incidence rates between developed and developing countries. [Frazer, 2004; Sankaranarayanan and 
Ferlay, 2006; Jemal et al., 2011]. Interestingly, the incidence of cervical cancer has been 
changing in developed countries: while in early 50’s the incidence started to increase due to 
the appearance of better diagnostic tools, in early 90’s it has started to decrease due a better 
clinical approach and better use of preventive measures.  
Nowadays, it is established that the persistent infection by one or more carcinogenic types of 
Human Papillomavirus (HPV) is the main etiological factor for cervical cancer development. 
[zur Hausen, 1991; zur Hausen, 2009a; Zur Hausen, 2009b; Zur Hausen and Rosl, 1994]. The 
procedures for cervical cancer detection and screening are based in screening programs with 
cytology (Pap smear test) and more recently with the detection of HPV DNA. The 
establishment of coordinated screening programs has reduced substantially rates of incidence 
and mortality of cervical cancer, however, clinicians still demand for the identification of 
useful predictive/prognostic biomarkers for HPV infection and progression of lesions. 
The majority of HPV infections are asymptomatic and are efficiently controlled by the 
immune system, therefore, the outcome of HPV infection is variable and the infection is 
usually transient and complete resolution is generally common within 6 to 12 months [Ho et 
al, 1998; Woodman et al, 2007]. However, persistent infection with one or more carcinogenic 
types of HPV may lead to the development of intraepithelial lesions, which may progress to high-
grade dysplasia or in severe cases to invasive carcinoma [Woodman et al, 2007]. 
 4| Genetic Markers of HPV Infection and Cervical Cancer: Clinical Utility 
In the past decade there have been several studies that attempt to develop proof-valuable 
biomarkers for HPV infection outcome based on the distinct events of HPV-related 
carcinogenesis and cellular modifications caused by HPV infection (Hwang et al, 2012). 
Recent data point to the importance of microRNAs (miRNAs) in different cancers. These 
single-stranded RNAs sequences (~22 nucleotides) participate in several cellular processes, 
regulating up to 30% of human protein-coding genes, by suppressing RNA translation or 
inducing messenger RNA (mRNA) degradation. Hence, miRNAs are thought to represent a 
new approach in the diagnosis and prognosis of cervical cancer [Melo and Esteller, 2011; 
Pereira et al, 2010]. Moreover, the identification of different tumor-specific microRNA 
signatures could be very helpful to distinguish pre-malignant lesions from invasive cancers. In 
fact, studies have been described several interactions between microRNAS and HPV 
oncoproteins and recent data have been demonstrated that several miRNAs are deregulated 
and presents abnormal expression in lesions and cancer tissues of the cervix [Wang et al, 
2008; Pereira et al, 2010, 2007; Martinez et al, 2008]. 
The main aim of this thesis is to characterize the expression of two miRNAs (miR-125b and 
miR-34a) in different cervical lesions including cancer. Both miR-125b and miR-34a have 
been described as interacting in crucial steps of cancer development. By characterizing the 
expression of miR34 and miR125b in cervical lesions we expect to be able to associate levels 
of expression with different outcomes of HPV infection and cervical lesions; and therefore to 
determine the impact of these miRNAs as predictive/prognostic biomarkers.  
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ROLE OF MICRORNAS IN CERVICAL CANCER: ARE MIR-125B AND MIR34A 
GOOD BIOMARKERS?   
Joana Ribeiro
1, 2, 4 
and
 
Hugo Sousa
2, 3
 
1
Faculty of Medicine, University of Porto, 
2
Virology Service 
3
Molecular Oncology Group, Portuguese Institute 
of Oncology of Porto, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal; 
4
Portuguese League 
Against Cancer, Núcleo Regional do Norte, Portugal 
 
Abstract 
MicroRNAs are non-coding RNAs with important functions in several biological processes, 
such as, regulation of cell cycle, immune response, inflammation, and apoptosis. In fact, 
deregulation and abnormal expression of these molecules is associated with human 
pathologies including cancer and several have already emerged as potential prognostic 
biomarkers in different neoplasias. miR-34a is directly regulated by p53 and acts as tumor 
suppressor while miR-125b plays a significant role in immune response and apoptosis. In 
cervical carcinogenesis, HPV proteins seem to interact with both miR-34a and miR-125b 
changing its expression and promoting persistent infection and cervical cancer development. 
In this review we describe the potential role of miR-125b and miR-34a in cervical 
carcinogenesis, including interaction with HPV and mechanism of deregulation. Additionally, 
their clinical applications in cervical cancer as prognostic/predictive biomarkers are also 
briefly discussed.  
 
Keys words: 
Cervical cancer, HPV infection, miR-34a, miR-125b, biomarkers 
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Cervical Cancer and HPV carcinogenesis  
Worldwide, cervical cancer is the third most commonly diagnosed cancer in females with 
approximately 530 000 of new cancer cases each year and a total of 275 100 deaths among 
females in 2008 [1]. However incidence rates show to be different between developed or 
developing countries. Recent data reveals that cervical cancer is extremely common in 
countries such as Central and South America, Eastern Africa and South-East Asia in contrast 
to developed counties [2; 3]. Over the past 100 years, the incidence of cervical cancer has 
been changing a lot in developed countries. While in early 50’s the incidence started to 
increase due to the existence of better diagnostic tools, in early 90’s it has started to decrease 
due a better clinical approach and better use of prevention measures.  
The use of Pap smear test in screening programs has proved to be useful for the prevention 
of cervical cancer in the last 30 years. Although histological examination of colposcopy-
guided biopsies is still considered the confirmatory exam in the assessment of cervical 
lesions, screening with cytological examination is the most used worldwide. This technique 
is limited to the interpretation of the morphological alterations of tissues and do not provide 
information regarding the infection and the risk of progression [4]. 
Since early 90’s that scientific community understands better the carcinogenic model of 
cervical cancer. There were many studies until the clear observation that persistent infection 
with one or more carcinogenic types of human papillomavirus (HPV) was the etiological 
factor for the development of cervical cancer and that the infection of cervix by HPV is 
followed by a cascade of events that lead to the development of squamous intraepithelial 
lesions of the cervix which may progress to high-grade dysplasia or to invasive carcinoma 
[5; 6].  
In the past decade there have been several studies that attempt to develop proof-valuable 
biomarkers for HPV infection outcome based on the distinct events of HPV-related 
CHAPTER II 
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carcinogenesis and cellular modifications caused by HPV infection [7]. The greatest 
hallmark of HPV-associated carcinogenesis is thought to be the integration of the viral 
genome into the host genome. This event leads to HPV-E2 gene disruption and therefore 
deregulating both viral and host genome activity. The loss of HPV-E2 results in the 
constitutive expression of both HPV-E6 and HPV-E7 proteins leading to oncogenic 
transformation of cells: HPV-E6 binds p53 inducing its degradation by the ubiquitin-
proteasome pathway promoting p53-dependent apoptosis activation; and HPV-E7 modifies 
pRb phosphorylation promoting cell cycle checkpoints escape and cell proliferation [8; 9]. 
Despite these evidences, the utility of HPV-genome integration into host-cells as a 
biomarker in clinical decision is doubtful and therefore several other biomarkers have been 
studied, such as viral load, detection of E6/E7 mRNA and expression of p16 in cervical 
tissues [7]. Recently, scientific community has started to debate whether miRNAs can be 
used as possible markers for the occurrence and development of the HPV-associated 
cancers. 
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MicroRNAs 
Small non-protein-coding RNAs are rising as a new class of regulatory genes with significant 
relevance in cellular processes. In 1993, small RNAs were first described as essential 
regulators for post-embryonic development of Caenorhabditis elegans [10; 11], and since 
2001 designated as “microRNAs” [11; 12; 13]. microRNAs (miRNAs) are small non-coding 
RNAs of 18-25 nucleotides in length (see miRBase, http://microrna.sanger.ac.uk/), generated 
from hairpin transcripts, that potentially target up to one-third of human coding genes 
managing normal cellular processes, including proliferation, differentiation and apoptosis [10; 
11; 14; 15; 16; 17]. Additionally, they are described as key regulators in many diseases 
including, neurological disorders, cardiovascular diseases, viral infections and cancer [18]. 
MicroRNA genes are thought to be located in the introns or long non-coding RNAs 
transcripts, as well in independent transcription units with specific promoters and 
polyadenylation signals [17]. Approximately 50% of mammalian microRNA loci are close to 
other miRNAs regions and are transcribed as polycistronic messages in single transcript units 
or are overlapped in the host transcripts, within exons or introns, depending on the splicing 
processes [17]. 
Structurally, miRNAs are part of a long transcript known as pri-miRNA (hairpin precursor) 
that contain a 5ʹ-cap structure, a poly(A)+ tail, a stem–loop structure and also may include 
introns. In the nucleus, pri-miRNA is processed by Drosha complex into pre-miRNA (~70 
nucleotides) that are exported to cytoplasm by exportin-5 and cleaved by the Dicer complex 
to become a mature duplex miRNA [15; 17; 19]. This duplex miRNA, which includes two 
strand: the miRNA-5p and the complementary strand known as miRNA-3p, is then uncoiled, 
and while the mature miRNA (also known as guide strand) is loaded into the RNA-induced 
silencing complex (RISC) the other strand (passenger strand) is usually degraded [15; 19].  
CHAPTER II 
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MicroRNAs and Cancer 
The aberrant expression or alterations of miRNAs are associated with human pathologies, 
including cardiovascular disorders, inflammatory diseases and cancer [20; 21]. Studies have 
confirmed that miRNAs are able to regulate the expression of 30-60% of human proteins [11]. 
These small molecules are thought to regulate gene expression by binding mRNA targets and 
promoting their degradation and/or translational inhibition, although, some studies suggested 
that miRNAs can also increase the expression of a target mRNA [17]. Nucleotides 2–7 of the 
miRNA are nominated by “seed region” and they are responsible for binding specificity to the 
target mRNA. However, recent data pointed that not only these molecules can target mRNA 
but also DNA and proteins [17]. Another important fact of these molecules is that each 
miRNA may target several different mRNAs and a single mRNA can be targeted by several 
miRNAs [17]. 
Recent studies have suggested that deregulation of miRNAs caused by both genetic and/or 
epigenetic mechanisms potentiate cancer development [17]. In fact, genome-wide 
transcriptional analysis have showed that the profile of miRNA expression seems to be 
sufficient to classify a variety of human cancer suggesting a diagnostic value for these 
molecules [22]. Moreover, differences in miRNA expression profiles seem to define specific 
signatures of various cancers and even allow identifying specific oncogenic abnormalities [11; 
14]. 
Several studies have been addressing on the impact of miRNAs in tumor development and 
consequently the number of these molecules involved in human cancer has been growing 
[11]. The biological functions of miRNAs are highly dependent on cellular context, which 
may be due to differential expression of their target mRNAs. miRNAs are known to act as 
both regulators and targets of oncogenes and tumor suppressor genes depending on specific 
tissues genes by modulating the levels of specific proteins with tumor suppressor or 
 12 | Genetic Markers of HPV Infection and Cervical Cancer: Clinical Utility 
oncogenic potential (Table I) [11; 18]. Further understanding of the expression and function 
of miRNAs in different cancers is thought to provide in the near future the development of 
better diagnostic and therapeutical approaches against cancer, mainly by allowing the 
identification of pre-neoplastic lesions and better follow-up of patients [23].  
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MicroRNAs and cervical cancer  
Recent studies suggest miRNAs as possible markers for the occurrence and development of 
the HPV-associated cancers and the differences in tumor-specific miRNA signatures might 
be helpful to distinguish different cervical lesions [24]. Studies have been describing several 
interactions between miRNAs and HPV oncoproteins [25; 26; 27] and, in fact, specific 
miRNAs have been located in cancer-related genomic regions, which include fragile sites at 
or near HPV integration sites [28]. Moreover, recent studies using microarrays methods have 
characterized the expression of several miRNAs in cervical tissues [24; 29].  
Microarrays analysis have demonstrated that miRNAs involved in important cell events, such 
as miR-21, miR-24, miR-155, and miR-205 are up-regulated, whereas many others are down-
regulated (eg. miR-100, miR-let7b, miR-143, miR-145) [29]. Li et al, 2011 have also 
described that miR-100 is significantly and gradually reduced from pre-neoplastic lesions to 
invasive cervical cancer [30]. Nevertheless, the author has shown that E7/E6 expression did 
not change miR-100 levels and therefore, it is still unknown if the downregulation is a cause 
or consequence [30; 31]. Moreover, in vitro experiments have been performed to study 
interactions between microRNAs and HPV oncoproteins with interesting interactions 
observed [27; 30; 31; 32]. 
In this review, we aimed to describe the mechanisms of miR-34a and miR125b in cervical 
cancer development. Additionally, their potential clinical applications and prospects in 
cervical cancer, such as biomarkers and clinical therapies, are also briefly discussed. 
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miR-125b 
miR-125 is a highly conserved miRNA common among various species. In humans, miR-
125 family is constituted by three homologs (hsa-miR-125a hsa-miR-125b-1 and hsa-miR-
125b-2) whose genes are located in different chromosomes (chr19q13, chr11q24 and 
chr21q21, respectively) (see mirBase: http://microrna.sanger.ac.uk/). Despite different 
location within the genome, they have the common primary transcript that also contains the 
miR-99/miR100 and let7 family member. Although it remains unclear if the three different 
miRNAs produced by the transcript are functionally linked, it is supposed that duplicated 
clusters are under distinct transcriptional control displaying different expression patterns and 
functions  [33]. 
The study of miR-125b family expression is still controversial, with some results showing 
that it depends on the type of tissue, mainly due to the tissue microenvironment. As a result, 
miR-125b has been described as potentially involved in inflammation, cell proliferation and 
cell cycle regulation which makes it difficult to fully characterize this molecule in different 
diseases [20; 34; 35; 36]. 
miR-125b is thought to act as both oncogene and tumor suppressor: while overexpression of 
miR-125b is reported in prostate cancer and hematological malignances, where it seems to act 
as oncogene [37; 38; 39]; down-regulated expression has been described in breast, ovarian, 
hepatocellular and thyroid carcinomas, therefore assuming a tumour suppressor role [36; 38; 
40]. In fact, Zhang and colleagues proved that miR-125b expression in breast cancer cells 
suppress proliferation and induces G1 cell-cycle arrest [36; 41]. 
Despite its involvement in different pathways, miR-125b was described as a negative 
regulator of p53 and therefore regulates the potential p53-dependent transactivation activity, 
thus leading to increased cellular instability and ultimately decreased apoptosis [35; 41]. The 
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oncogene/tumor suppressor balance is probably explained by the direct interaction of miR-
125b with apoptosis, where it seems to play a major cellular role: either by suppressing the 
pro-apoptotic molecule Bcl-2 Antagonist Killer 1 (Bak1) (anti-apoptotic role); or by 
regulating the expression of Mcl-1, Bcl-w and IL-6R (pro-apoptotic role) [42]. Additionally, 
studies have reported that miR-125b is also able to suppress cell proliferation and promote 
apoptosis by targeting ERBB2, ERBB3, ETS1 and Bcl-2 [36; 38; 43].  
In the past years, miR-125b has also been studied in viral associated diseases due to its 
possible role in inflammation and immune response regulation [44; 45]. Wang and colleagues, 
using microarray data, have described that miR-125b is down-expressed in cervical cancer 
due to its possible interaction with HPV proteins, a theory that Li and colleagues have 
corroborated [29; 31]. Literature also reveals that there is a strong homology between miR-
125b and the HPV-L2 protein from different HPV genotypes, suggesting a possible direct 
interaction between miR-125b and HPV. Nuovo and colleagues revealed that HPV-L2 
induces inactivation of miR-125b in HPV infected cells and that this event seems to be 
associated with cytological changes of the koilocytes [46]. These data also point to a marked 
reduction of miR-125b expression in HPV-infected tissues when compared to normal tissues. 
Up to date, there is no clear explanation about the biological processes that leads to miR-125b 
down-regulation, nevertheless, it is plausible to presume that this molecule might play some 
role in HPV-associated cancer development. Moreover, authors are suggesting that it could be 
used as potential prognostic marker predicting HPV outcome and cervical lesions progression. 
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miR-34a 
The miR-34 family is composed by three miRNAs (miR-34a, miR-34b and miR-34c) encoded 
by two different genes: miR-34a is encoded by its own transcript located at 1p36; whereas 
miR-34b/c share a common primary transcript at chromosome 11q23.1 (see mirBase: 
http://microrna.sanger.ac.uk) [23]. Genome analysis reported that both genes have a proximal 
promoter region that contains a p53 binding site, thus members of the miR-34 family are 
described as direct p53 targets and by targeting miR-34 family, p53 is able to induce 
apoptosis, cell cycle arrest and senescence [23; 25; 26; 47; 48; 49]). In fact, several studies 
have shown that miR-34a seems to be the most significantly induced miRNA after activation 
of p53 and therefore p53 can regulate the expression of several proteins, even after their 
mRNAs have already been translated [Bommer et al., 2007; Chang et al., 2007; He et al., 
2007a; He et al., 2007b]. In the presence of cellular stress, this type of regulation becomes 
more advantageous because it does not need the translation of additional effector proteins, 
which might take long time to act [23]. 
Despite the majority of studies have implicated the miR-34 family in the p53-network, 
induced by p53-dependent DNA damage pathway, the consequences of miR-34 activation 
may vary depending on cellular context [He et al., 2007a; He et al., 2007b]. Bioinformatics 
systems have been used to predict miR-34 targets providing a better knowledge of its wide-
spectrum. Moreover, some of these targets were already validated by experimental analysis 
and the different roles may depend on the spectrum of miR-34 targets expressed in a specific 
cell type [He et al., 2007a; He et al., 2007b]. Bommer et al showed that miR-34a is expressed 
at higher levels than miR- 34b/c with the exception of the lung, where these two miRNAs are 
presumed to have specific functions [23; 47]. 
Considering that miR-34 family is induced by p53, several studies have been preformed to 
evaluate the role of miR-34s, especially miR-34a, in different cellular processes in different 
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neoplasias. Taking into account the role of miR-34 in cell-cycle arrest, senescence and 
apoptosis as tumor suppressor gene, its permanent inactivation, may be a selective advantage 
for cancer cells [23]. Decreased expression of miR-34s can be brought to epigenetic 
mechanisms and mutations of miR-34-encoding genes as well as to mutations and viral 
inhibitors of p53 [23]. In fact, miR-34 has been reported as donwn-regulated and/or 
inactivated in several types of cancer, including lung, ovarian, colorectal, pancreatic, 
urothelial, and renal cell carcinomas [50; 51; 52]. 
miR-34 family has also been studied for its role in cervical cancer development based on the 
possible interaction with HPV proteins [53; 54] Recently there were described evidences that 
expression of miR-34a is significantly lower in High-Risk HPV (HR-HPV) infected tissues 
[Li et al., 2010]. These evidences associate reduced miR-34a expression with HR-HPV 
infection and cervical cancer development. In cervical carcinogenesis, HPV-E6 oncoprotein 
binds to p53 targeting its degradation trough the ubiquitin-dependent proteasome system [9].  
The inactivation of p53 leads to a diminished amount of protein available to bind miR-34 p53 
binding site promoter region, thus leading to a down-regulation of miR-34a expression in 
most HPV infected tissues. This theory is supported by some studies that associate viral E6-
mediated reduction of p53 and miR-34a family contributes to cell proliferation and 
transformation [23; 54]. 
Actually, further studies are need for a better clarification of the biological processes by 
which miR-34 is down-regulated in cervical carcinogenesis. Moreover, studies evaluating 
miR-34 levels in cervical lesions and cancer might be important for prediction of HPV 
infected patients outcome. 
Final conclusions  
In this article we summarized the current knowledge about the potential role of miR-34a and 
miR-125b in cervical cancer development. Both miR-34a and miR-125b seems to present 
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abnormal expression levels in cervical cancer. These two molecules interact with distinct 
targets and therefore play different functions in important processes, such as, inflammation, 
immune response, cell cycle, apoptosis and proliferation. 
miR-34a is a downstream target of p53-network with key functions in the inactivation of 
several proteins involved in apoptosis, G1-arrest, DNA repair and senescence. This regulation 
is essential for the maintenance of cellular stability and therefore in normal cases, in the 
presence of cellular stress the activation of p53-network will allow cells to avoid the 
accumulation of errors and ultimately the development of neoplastic cells. After HPV 
infection, the activation of p53 is crucial for the control of cell proliferation. Now, we clearly 
understand that HPV is highly effective in the abolishment of efficient immune response to 
infected cells, mainly by promoting HPV-genome integration into host cells. The integration 
of HPV-genome leads to the expression of HPV-E6 protein that targets p53 to degradation 
trough the ubiquitin-proteasome pathway. Thus, with a decreased availability of p53, the 
amount of miR-34a will be decreased and therefore its ability to inactivate some proteins 
involved in apoptosis, G1-arrest, DNA repair and senescence will allow cells to proliferate and 
therefore contribute for the development of a neoplastic lesion (Figure 1).  
Literature data reveals that miR-125b is a negative regulator of p53 and therefore acts 
upstream p53 activation. Increased levels of miR-125b are thought to abolish p53 functions 
by targeting its mRNA and therefore inducing a decreased activation of p53-dependent 
apoptosis and increasing cellular instability by avoiding G1-arrest and DNA repair. Moreover, 
there are some data that refer miR-125b as having an important role in immune response and 
inflammation. After HPV infection it is expected that HPV would replicate and infected more 
cells. This process is dependent on effective production of HPV-virions and studies have 
confirmed that miR-125b has strong homology for HPV-L2, which is crucial for the viral 
capsid assembly. These data suggest that miR-125b may probably be involved in two distinct 
CHAPTER II 
 
Genetic Markers of HPV Infection and Cervical Cancer: Clinical Utility | 19 
pathways of HPV-associated carcinogenesis. On one hand it is expected that after early 
infection it will avoid HPV replication and therefore could improve viral clearance. 
Nevertheless, mirR-125b will also lead to p53-pathway inactivation and therefore cells will be 
maintained viable with viral genomes inside. This may lead to the increase risk of HPV-
genome integration and therefore to increased risk of neoplastic lesion development (Figure 
1).  
Considering all these data, it is possible that while miR-125b may assume an important role 
on the initial steps of cervical carcinogenesis, including inflammation and immune response 
against HPV infection, miR-34a is probably more important in the development of high-grade 
cervical intraepithelial lesions. This is a theoretical model that still requires confirmation by 
expression or in vitro studies to confirm if miR-34a and/or miR-125b can be used as 
predictive/prognostic markers in the different steps of cervical carcinogenesis. 
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Table I – Human miRNAs targets and functions in carcinogenesis 
 
Human miRNA Targets Activity Reference 
Let-7 family 
CDC25A 
CDK6 
c-myc 
RAS 
Tumor suppressor 
[55] 
[56] 
miR-9 E-cadherin Tumor suppressor [57] 
miR-15-16 cluster Bcl2 Oncogene 
[58] 
[59] 
miR-18 ATM Oncogene [60] 
miR-21 
hMSH2 
CDC25A 
Bcl2 
Oncogene 
[61] 
[62] 
[63] 
miR-34a 
Bcl2 
Survivin 
CDK4 
CDK6 
Cyclin D1 
Cyclin E2 
c-Myc 
E2F3 
C-Met 
SIRT1 
MTA2 
WNT1 
LEF1 
Tumor suppressor 
[25] 
[23] 
miR-124a CDK6 Tumor suppressor [64] 
miR-125b 
p53 
Bak-1 
Oncogene [42] 
ERBB2 
ERBB3 
ETS1 
Bcl-2 
Mcl-1 
Bcl-w 
IL-6R 
Tumor suppressor 
[43] 
[36] 
[38] 
miR-137 CDK6 Tumor suppressor 
[64] 
[65] 
miR-146b NF-kappaB Tumor suppressor [66] 
miR-205 
E2F1 
LAMC1 
Tumor suppressor [67] 
miR-221 
p27 
p57 
Oncogene [68] 
miR-421 ATM Oncogene [69] 
miR-504 p53 Oncogene [70] 
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Figure 1 - miR-34a and miR-125b interactions and association with HPV  
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ABSTRACT  
Background: Cervical cancer development is associated with persistent infection by high-
risk types of human papillomavirus (HPV) and its detection and genotyping is considered to 
be crucial to identify women with increased risk of cervical cancer development. Different 
prevalence of HPVs has been reported in distinct populations and therefore its distribution 
may determine future clinical approaches and improve the intervention on vaccination 
programs. 
Material and Methods: This study was performed with cervical samples from 95 women 
with histological confirmation of cervical lesions. HPV was detected by Hybrid Capture 2 
(HC2) and genotyping was performed by polymerase chain reaction and restriction fragment 
length polymorphism (PCR-RFLP) using a protocol previously described.  
Results: HPV infection was detected in 42.9% (18/42) of women without lesions, 63.6% 
(14/22) of cervical intraepithelial neoplasia grade 1, 85.7% (6/7) of cervical intraepithelial 
neoplasia grade 2, 100% (12/12) of cervical intraepithelial neoplasia grade 3, and 100% (8/8) 
of cervical carcinomas. Statistical significant differences were found when performing age-
stratification of women according to age of 45 years old (p=0.021; OR=2.78). Overall 16 
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distinct HPV genotypes were detected: 9 high-risk (HPV16, 18, 31, 33, 39, 52, 56, 58 and 59), 
2 probable high-risk (HPV53, 66, 82) and 3 low-risk (HPV11, 61, 70). The most prevalent 
type was HPV16 (40.8%) followed by HPV31 (12.2%), HPV58 (10.2%), HPV39 (6.1%) and 
HPV53 and 66 (3.8%, each).  
Conclusion: This study provides confirms that HPV16 and HPV31 followed by HPV58, 39, 
53 and 66 are the most frequent HPV genotypes and that HPV18 is a rare genotype in our 
population. This information should be included in future approaches, mainly in the decision 
of future vaccination programs in Portugal. 
 
Keys words: 
Human Papillomavirus genotypes, integration, cervical cancer 
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INTRODUCTION 
Worldwide, cervical cancer is the third most commonly diagnosed cancer in females with 
approximately 530 000 new cancer cases and 275 100 deaths each year. In Portugal, cervical 
cancer is the 4th most frequent cancer with 950 new diagnosis and 378 deaths per year 
[Jemal et al., 2011; Pinheiro et al., 2003]. 
Since early 1990´s that persistent infection by high-risk HPVs is recognized a necessary but 
non-sufficient condition for the development of cervical cancer [zur Hausen, 1991; zur 
Hausen, 2009a; Zur Hausen, 2009b; Zur Hausen and Rosl, 1994]. Human papillomavirus 
(HPV) infection is highly prevalent in sexually active women. Despite majority of HPV 
infections spontaneously regress in a small percentage of cases the infection persists leading 
to development of low-grade intraepithelial lesions (LSIL) that might progress to high-grade 
intraepithelial lesions (HSIL) and, ultimately, develop invasive cervical carcinoma [Woodman 
et al., 2007].  
Pap smear test is actually the most commonly used screening procedure throughout the world 
for the diagnosis of cervical lesions. However, the detection of HPV DNA has been described 
as a sensitive test and therefore it has been implemented in some countries [Kuhn et al., 2000; 
Salmeron et al., 2003; Villa, 2006]. Recently, with the development of genotyping techniques, 
HPV genotyping allows to indentify women with persistent infection and consequently with 
increased risk to malignance progression. Integration of HPV genome into the host´s genome 
is considered the hallmark of HPV-associated carcinogenesis and has been suggested as 
another important tool to select women with increased risk of cervical cancer, however, the 
significance of HPV physical status detection remains unclear [Janicek and Averette, 2001; 
Pett and Coleman, 2007; Ramanakumar et al., 2010]. 
HPV types have been divided into four groups based on their oncogenic activity: high-risk 
(HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), probable high-risk (26, 53, 66, 68, 
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73, and 82), low-risk (6, 11, 13, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 89), and unknown-
risk types (30, 32, 34, 62, 67, 69, 71, 74, 83, 84, 85, 86, 87, 90, and 91) [de Villiers et al., 
2004; Munoz et al., 2006; Nobre et al., 2008]. Different prevalence of HPV have been 
reported in distinct populations and therefore it is important to characterize the most 
prevalent genotypes in specific population that will improve the clinical approach and also 
improve the intervention on vaccination programs [Bruni et al., 2010; de Sanjose et al., 
2007; de Sanjose et al., 2010].  
There are few studies indicating HPV genotypes prevalence between Portuguese populations 
and therefore we aimed to characterize HPV genotype profile in women from northern region 
of Portugal and determine the physical status of HPV in cases with HPV-16 infection. 
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SUBJECTS, MATERIALS, AND METHODS 
Study population  
This study was performed with exfoliated cervical cells collected from 95 inpatient women 
with median age of 42±13.1 years old at the Portuguese Institute of Oncology of Porto. All 
samples were submitted to cytological examination and classified according to the Bethesda 
classification with the final diagnosis of the women to be confirmed by histological evaluation 
by experimented pathologists from our institution. Of the 95 patients examined, histological 
classification revealed 13 normal cervical epithelium (median age 49.0±11.0), 30 cervicitis 
(median age 44.0±12.8), 24 cervical intraepithelial neoplasia grade 1 (CIN1) (median age 
37.5±9.43), 7 cervical intraepithelial neoplasia grade 2 (CIN2) (median age 38.0±9.25), 12 
cervical intraepithelial neoplasia grade 3 (CIN3) (median age 45.5±10.8), 4 carcinoma in situ 
(CIS) (median age 48.0±19.5) and 5 invasive cervical carcinomas (ICC) (median age 
75.0±20.8). Correlation between histological and cytological exams is described in Table I. 
 
Sample processing 
Samples were collected in ThinPrep
®
 tubes (Hologic, USA) and stored at room temperature 
prior processing. A 4ml aliquot was prepared for digene HC2 High-Risk HPV DNA Test 
(QIAGEN, Germany) and 1ml aliquot was used for nucleic acid extraction. Total nucleic 
acids extraction was performed using High Pure Viral Nucleic Acid kit (Roche, Germany), 
according to manufacturer’s instructions, and DNA/RNA quality was assessed by measuring 
the absorbance at 260/280nm. The presence of amplifiable genomic DNA was also tested 
with a PCR protocol for amplification of a beta-globin gene with the PCO3 primer 5’ – ACA 
CAA CTG TGT TCA TAG C – 3’ and BGII primer 5’ – GTC TCC TTA AAC CTG TCT TG 
– 3’. 
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The PCR reaction was performed in a 50μl solution with 1x Taq buffer, 2.0mM MgCL2, 
0.2mM DNTP’S, 0.30μM each primer, 1U of Taq DNA Polimerase and 0.2ug of genomic 
DNA. The amplification conditions were as following: denaturation of DNA template at 95ºC 
for 3 min, followed by 35 cycles of 94ºC for 1min, 55ºC for 1min, and 72ºC for 1min, and a 
final extension step at 72ºC for 10min. The amplified fragment of 175 base pairs (bp) was 
analyzed by electrophoresis in 1.5% (w/v) agarose gels stained with ethidium bromide and 
visualized under UV light.  
 
HPV characterization  
HPV infection was detected by digene HC2 High-Risk HPV DNA Test (QIAGEN, Germany) 
(HC2) at the Virology Service of IPO Porto as part of routine procedures. 
HPV DNA was also detected through PCR, using the MY09/11 degenerated primers, which 
amplify a region of 449–458bp depending on HPV type. These primers amplify a highly 
conserved region of the HPV L1 gene and are potentially capable of detecting a large number 
of mucosal HPV types in a single PCR reaction (16).  
PCR was performed in a 50µl of reaction mixture with 1x PCR Buffer, 4.0mM MgCl2, 
0.2mM DNTP’S, 0.40µM of each primer, 1U of Taq DNA polymerase and 0.2ug of DNA. 
The amplification conditions include an initial denaturation step at 95ºC during 3min, 
followed by 40 cycles of 94ºC for 45s, 55ºC for 45s, and 72ºC for 1min and a final extension 
step at 72ºC for 5min. The amplified fragment was analyzed by electrophoresis in 1.5% (w/v) 
agarose gels stained with ethidium bromide and visualized under UV light. 
HPV-positive cases were typed by restriction fragment length polymorphism (RFLP) analysis 
as described by Nobre et al. 2008 [Nobre et al., 2008]. Each restriction endonuclease reaction 
was performed in a 20μL final volume reaction, using 5μL of MY09/11 PCR product, 2μL of 
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10x recommended restriction buffer, and 10units of each restriction endonucleases: PstI (New 
England BioLabs, R0140S), HaeIII (Fermentas Inc., #ER0151, Canada), DdeI (New England 
BioLabs, R0175L) and RsaI (New England BioLabs, R0167S). Digestion was performed at 
37ºC for 5 hours. The restricted fragments were separated by electrophoresis. The 
identification of HPV types was executed using the algorithm proposed by Nobre et al, 2008 
[Nobre et al., 2008] and HPV genotypes were classified into four groups based on their 
oncogenic activity: high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), 
probable high-risk types (26, 53, 66, 73, 82), low-risk types (6, 11, 13, 40, 42, 43, 44, 54 and 
55, 61, 70, 72, 81 and 89) and types of undetermined-risk (30, 32, 34 and 64, 62, 67, 69, 71, 
74, 83, 84, 85, 86, 87, 90, 91, 97, 102, 106) [Munoz et al., 2006; Nobre et al., 2010].  
 
HPV-16 integration  
The physical status of HPV16 was analyzed using a multiplex Real-time PCR that allows 
simultaneous amplification of the E2 and E6 regions [Canadas et al., 2010]. 
PCR reaction was performed in a 50µl of reaction mixture, including 0.2ug of DNA, 1x 
Universal Real-Time Master Mix (Applied Biosystems, Foster City, California USA), 30pmol 
of E2 forward and reverse primers, 6pmol of E2 probe, 3pmol of E6 primers and 1pmol of E6 
probe. The amplification conditions include one step at 50ºC for 2min, followed by 45 cycles 
of 95ºC for 1 min, 55ºC for 1 min and 72ºC for 1min. HPV-16 status classification was based 
on the principle that, when integration occurs, the E2 gene is partially or totally disrupted 
while the E6 gene remains intact [Canadas et al., 2010]. 
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Quality Criteria 
To ensure the quality of the study we have defined the following quality criteria: 1) inclusion 
of negative and positive controls in all PCR reactions (as negative controls we have used 
double distilled water replacing template DNA and as positive control we used a sample from 
the External Quality Control Panel of the Virology Service for the diagnosis of HPV 
infection; 2) repetition of 100% of samples for validation of results; and 3) analysis of all 
results by two independent researchers. 
 
Statistical Analysis  
Statistical Analysis was performed using the computer software IBM
®
 SPSS
®
 (Statistical 
Package for Social Sciences) Statistics version 20.0 for Mac. Frequencies among groups were 
compared, whenever appropriate, by Student’s t-test, ANOVA and Chi-square (χ2) test. 
Results are considered significantly different when P<0.05. The OR (Odds Ratio) and its 95% 
confidence interval were calculated as a measure of the association between categorical 
variables. 
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RESULTS 
 
HPV frequency  
Correlation of HC2 results was performed with MY09/11 PCR in 88 samples with adequate 
quality of DNA (Table II). The presence of inconclusive results was similar in both HC2 and 
PCR test (n=3 and n=4, respectively). However, we observed 7 positive cases detected by 
HC2 without amplification in PCR. As expected, the inverse correlation happens in 2 cases of 
low-risk HPVs. In general, our results suggest that the results obtained by two techniques 
were consistent (Table II). 
Considering results obtained by HC2, HPV infection was detected in 63.7% (58/91) of the 
cervical specimens (4 cases were considered inconclusive by the test). HPV infection was of 
38.5% (5/13) for normal samples, 44.8% (13/29) for cervicitis, 63.6% (14/22) for CIN1, 
85.7% (6/7) for CIN2, 100% (12/12) for CIN3, 100% (4/4) for CIS and 100% (4/4) for ICC 
(Table III).  
HPV infection was stratified according to four different age groups (<35, 35–45, 45-55, >55 
years old) and results showed that HPV infection was more frequent in women younger than 
35 (77.8%) than in women aged 35–45 years old (69%), 45-55 years old (47.8) or older than 
50 years old (50%) (Figure 1). Statistical significant differences were found when comparing 
HPV infection among women younger than 45 and women older than 45 (p=0.021; OR=2.78, 
95% CI 1.15-6.73). 
Risk-association was estimated by statistical analysis considering that there were no 
difference between normal and cervicitis cases, which were grouped into a new group 
(women with no lesion); and CIN1 were categorized as LSIL and CIN2 and CIN3 grouped 
into HSIL. The analysis revealed a strong association between HPV infection and neoplasia 
development (OR=5.45; 95%CI 2.09–14.2; P=0.001) when comparing the prevalence of 
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HPV in all grades of neoplasia (low- and high-grade lesions and carcinoma) versus the 
reference category (normal and cervicitis). Moreover, statistical significant differences were 
found when comparing HPV distribution in different individual grades of lesions (Table IV).  
All positive cases (n=58) were genotyped in order to characterize the HPV population in our 
sample (Table III), nevertheless we were not able to genotype a total of 9 cases: 2 normal, 3 
cervicitis, 1 CIN1, 1 CIN2 and 2 CIS. Overall, 16 different types were detected: 9 high-risk 
(HPV16, 18, 31, 33, 39, 52, 56, 58, 59); 4 probable high-risk (HPV53, 66, 82, 83); and 3 low 
risk (HPV11, 61 and 70). Notably, in the present study, high-risk HPV types were more 
frequent (85.7%) than probable high-risk HPV types (8.2%) or low-risk (6.1%). The most 
frequent types of HPV found were HPV16 (single and co-infection, 42.9%) followed by 
HPV31 (12.2%) and HPV58 (10.2%) (Table V). In our population co-infections were 
uncommon since we only detected 2 cases with co-infection (HPV16+HPV83 and 
HPV53+HPV39). 
 
HPV16 integration  
We have been able to characterize HPV physical status in 19 out of the 21 positive samples 
for HPV16. The prevalence of HPV16 integrated forms was of 31.6% (6/19). There were no 
integrated forms found either in patients with cervicitis and CIN2. The prevalence of HPV-16 
integrated forms among CIN1 was of 40.0% (2/5), 33.3% (2/6) in CIN3, 100% (1/1) in CIS 
and 25.0% (1/4) in ICC (data not shown). Statistical analysis revealed no significant 
differences in HPV-16 integration distribution among the histological classification (p=0.578) 
or age groups (p=0.440) (data not shown). 
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DISCUSSION 
HPV infection is one of the most common sexually transmitted infections and a major public 
health concern [Ho et al., 1998; Moscicki et al., 2001]. Persistent infection with one or more 
carcinogenic types of HPV may lead to the emergence of intraepithelial lesions, which may 
progress to high-grade dysplasia or to invasive cervical carcinoma [Woodman et al., 2007]. 
One of the major problems in HPV characterization studies has been the reliability of 
cytological classification that commonly introduces biases in the analysis. In our study we 
have selected 95 patients attended at the Gynecological Service of our institution that have 
made a confirmatory biopsy after initial cytology. Surprisingly, our results showed that 42.9% 
of women without lesions (normal histology and cervicitis) of the cervix were positive for 
HPV infection. This frequency seems to be higher to those found in other studies, which refer 
that HPV infection among asymptomatic women may vary from 10 to 26% depending on the 
population[Bruni et al., 2010; de Sanjose et al., 2007; Pista et al., 2011a]. For intraepithelial 
lesions, including carcinomas, the prevalence of HPV infection was similar to recently 
described in worldwide studies [Bosch et al., 1993; de Sanjose et al., 2010; Medeiros et al., 
2005; Nobre et al., 2010; Smith et al., 2007]. 
Another common characteristic that is consistently described in literature is the correlation of 
HPV infection with age distribution, being the younger women most frequently found to be 
infected. As expected, we observed that HPV prevalence was significantly higher in younger 
women (p=0.021). This correlation might be explained by exposition to risk factors that are 
more frequent among young population and also to the development of acquired immunity 
over time after exposure[Franco and Cuzick, 2008; Silva et al., 2011]. 
HPV DNA analysis may be performed by several methodologies, and despite no significant 
differences, in our study HC2 proved to be more sensitive than MY09/11 PCR (data not 
shown). HC2 is probably the oldest method to detect HPV DNA, approved by Food and Drug 
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Administration (FDA, USA), and is still considered to be the “gold standard” for HPV DNA 
detection [Gravitt et al., 2000; Iftner and Villa, 2003].  
In order to improve the clinical utility of HPV detection, several methods are being developed 
to identify the different HPV genotypes. In our study, we have used the genotyping method 
described by Nobre et al, 2008, which allows a good discrimination of mucosal HPV types, 
including several HPV types that are underdiagnosed by HC2. Despite the HC2 test has been 
used to detect 13 high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
68) in our study we have found that there might be some cross-reactivity of HC2 HPV DNA 
probes with others HPV types (HPV 11, 53, 61, 66, 70, 82, and 83) that were detected in this 
study. 
Our study showed that high-risk HPV types are the most frequent, with HPV16 and HPV31 to 
have higher frequency. Despite HPV18 is the second most common high-risk type associated 
with cervical cancer, it was not among the most frequents in our population. In fact, HPV16 
has been described as the most prevalent type followed by HPV31 and HPV58 in European 
women, including in Portuguese population [de Sanjose et al., 2007; Medeiros et al., 2005; 
Nobre et al., 2010; Pista et al., 2011a; Pista et al., 2011b]. Currently underdiagnosed, HPV53 
and HPV66 have emerged between the most frequents, and scientific community has been 
debating is they must be considered probable high-risk or high-risk types [de Sanjose et al., 
2007; de Villiers et al., 2004; Medeiros et al., 2005; Nobre et al., 2010; Pista et al., 2011a; 
Pista et al., 2011b].  
Controlling HPV infection is thought to be the key to eradicate cervical cancer. Recent reports 
demonstrate that through HPV vaccination a promising prevention may be effective toward a 
reduction of the global burden of cervical cancer in 20 years [Franco and Cuzick, 2008]. An 
understanding of the epidemiology of HPV genotypes is important to improve screening 
programs of cervical cancer and to assessment of the impact of HPV16/18 vaccines. 
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According to several studies, over 70% of all cervical cancers are associated with HPV16 and 
HPV18 infection and therefore it is expected that the current prophylactic HPV16/18 vaccine 
will be effective in the prevention of cervical cancer in a significant women [Smith et al., 
2007]. However, our data suggests that in our population the existence of other types than 
HPV16/18 may reduce the impact of HPV vaccination programs in cervical cancer reduction. 
Thus, it is extremely important to develop epidemiological studies regarding HPV genotype 
characterization in populations to evaluate the cost-effectiveness of actual HPV vaccines and 
to predict the impact of new multiple-type vaccines in the near future. 
Recent studies have discussed the role of viral integration in cervical cancer development. 
Viral integration has been described as an indicator of increased risk to malignant progression 
[Hwang and Shroyer, 2012; Pett and Coleman, 2007; Ramanakumar et al., 2010]. In our 
study, we have tested for the characterization of HPV16 physical status, the most prevalent 
genotype. Results revealed that integrated forms are present in different lesions of the cervix 
whereas women without lesions had only episomal forms. Nevertheless, our study has few 
cases of HPV16 infection requiring further studies, preferably cohort studies, to follow-up 
normal and LSIL cases that are infected with HPV in integrated state and evaluate their 
progression. 
In conclusion, although the number of samples was limited and further large-scale 
epidemiological studies are needed to assess the significance of less common genotypes, this 
study provides a view on the spectrum of the most common mucosal HPV types in 
Portuguese women.   
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Table I – Correlation between histological and cytological classifications 
 
 Histological Classification 
C
y
to
lo
g
ic
a
l 
C
la
ss
if
ic
a
ti
o
n
 
 Normal Cervicitis CIN1 CIN2 CIN3 CIS ICC 
n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Normal  9 (28.1) 14 (43.8) 8 (25.0) 1 (3.1) --- --- --- 
ASC-US 4 (16.0) 12 (48.0) 5 (20.0) 1 (4.0) --- --- --- 
ASC-H --- --- 2 (100.0) --- --- --- --- 
LSIL --- 4 (22.2) 9 (50.0) 2 (11.1) 3 (16.7) --- --- 
HSIL --- --- --- 3 (23.1) 3 (23.1) 3 (23.1) 1 (7.7) 
CIS/ICC --- --- --- --- 1 (20.0) 1 (20.0) 4 (80.0) 
Total  (n=95) 13 (13.7) 30 (31.6) 24 (25.3) 7 (7.4) 12 (12.6) 4 (4.2) 5 (5.3) 
ASC-US, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells, cannot exclude high-grade; CIN, cervical intraepithelial neoplasia; CIS, 
carcinoma in situ; ICC, invasive cervical carcinoma; LSIL,  low-grade intraepithelial lesions; HSIL, high-grade intraepithelial lesions; 
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Table II: Correlation between HC2 and PCR results  
 
 
 PCR 
H
C
2
 
 
Negative Positive Inconclusive 
n (%) n (%) n (%) 
Negative (n=27) 25 (92.6) 2 (7.4) ---- 
Positive (n=57) 7 (12.3) 49 (86.0) 1 (1.8) 
Inconclusive (n=4) --- 2 (50.0) 2 (50.0) 
Total 32 (36.4) 53 (60.2) 3(3.4) 
HC2, hybrid capture 2; PCR, polymerase chain reaction 
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Table III: Distribution of HPV genotypes in study population.  
 
 
HPV Positive 
Total, n (%) Low-risk, n (%) High-risk, n (%) pHigh-risk, n (%) 
Normal (n=13) 5 (38.5) --- 2 (66.7) 1 833.3) 
Cervicitis (n=29) 13 (44.8) 2 (20.0) 7 (70.0) 1 (10.0) 
CIN I (n=22) 14 (63.6) --- 13 (100) --- 
CIN II (n=7) 6 (85.7) 1 (20.0) 3 (60.0) 1 (20.0) 
CIN III (n=12) 12 (100) --- 11 (91.7) 1 (8.3) 
CIS (n=4) 4 (100) --- 2 (100) --- 
ICC (n=4) 4 (100) --- 4 (100) --- 
Total (n=91) 58 (63.7) 3 (6.1) 42 (85.7) 4 (8.2) 
CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; ICC, invasive cervical carcinoma 
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Table IV: Prevalence of HPV infection in different lesions. 
 
 
HPV Negative HPV Positive 
P OR 95% CI P
a
 OR
a
 95% CI
a
 
n (%) n (%) 
Normal (n=13)  8 (61.5) 5 (38.5)  1.00 reference  1.00 reference 
Cervicitis (n=29)   16 (55.2) 13 (44.8) 0.700 1.30 0.34 – 4.94 0.748 1.25 0.32 – 4.91 
Without lesion (n=42) 24 (57.1) 18 (42.9)  1.00 reference  1.00 reference 
LSIL (n=22) 8 (36.4) 14 (63.6) 0.114 2.33 0.81 – 6.75 0.455 1.55 0.49 – 4.95 
HSIL (n=19) 1 (5.3) 18 (94.7) <0.001 24.0 2.93 – 196.8 0.005 21.3 2.55 – 176.8 
CIS/ICC (n=8) --- 8 (100) 0.003 NC NC 0.003 NC NC 
All lesions 9 (18.4) 40 (81.6) 0.001 4.74 1.82 – 12.4 0.001 5.45 2.09 – 14.2 
LSIL,  low-grade intraepithelial lesions; HSIL, high-grade intraepithelial lesions; CIS, carcinoma in situ; ICC, invasive cervical carcinoma; a, Adjusted for age; NC, not-
computable.  
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Table V: Distribution of different HPV genotypes 
 n (%) 
HR HPV (n=40)  
16 20 (40.8) 
18 1 (2.0) 
31 6 (12.2) 
33 2 (4.1) 
39 3 (6.1) 
52 1 (2.0) 
56 1 (2.0) 
58 5 (10.2) 
59 1 (2.0) 
pHR HPV (n=4)  
53 1 (2.0) 
66 2 (3.8) 
82 1 (2.0) 
LR HPV (n=3)  
11 1 (2.0) 
61 1 (2.0) 
70 1 (2.0) 
Co-infection (n=2)  
16 + 83 1 (2.0) 
39 + 53 1 (2.0) 
HR HPV, High-risk HPV; pHR HPV, Probable High-risk HPV; LR HPV, Low-risk HPV 
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Figure 1: Age-stratified HPV distribution.  
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ABSTRACT (202 words) 
Background: Clinicians are still demanding for predictive/prognostic biomarkers for HPV 
infection and cervical lesions progression. Recent studies suggested microRNAs as possible 
biomarkers of HPV-associated cancers, and therefore we aimed to characterize miR-125b and 
miR-34a expression in cervical samples.  
Methods: miR-125b and miR-34a expression was determined by qRT-PCR methodology in 
110 women with different cervical lesions: normal epithelium with (n=20) and without (n=29) 
HPV infection: LSIL (n=28); HSIL (n=21) and CIS/ICC (n=12).  
Results: We observed a two-fold increased miR-125b expression among normal cases with 
HPV infection (2
-ΔΔCt
=2.11; p=0.038). Data also showed a trend to down-regulation of miR-
25b in LSIL and HSIL cases and a significant decreased expression in women with either CIS 
or ICC (2
-ΔΔCt
=0.75; 2
-ΔΔCt
=0.78; 2
-ΔΔCt
=0.33 and 2
-ΔΔCt
=0.23, respectively). miR-34a 
expression analysis revealed an increased expression among women with normal cervix and 
HPV infection (2
-ΔΔCt
=1.69; p=0.049) but no significant change was observed for LSIL, HSIL 
or CIS/ICC.  
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Conclusion: This is the first study to characterize the expression of miR-125b and miR34a in 
cervical samples. Results showed that while miR-34a expression remains constant, miR-125b 
expression is significantly changed in the different cervical lesions and its levels should be 
further investigated as possible predictive/prognostic biomarkers using a non-invasive 
approach. 
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INTRODUCTION 
Cervical cancer is the third most common cancer among women with approximately 530 
000 new cancer cases and 275 100 deaths each year (Jemal et al, 2011; Pinheiro et al, 2003). 
Persistent infection by human papillomavirus (HPV) has been considered the etiological 
cause of squamous intraepithelial lesions of the cervix that may develop into high-grade 
dysplasia or to invasive carcinoma. High-risk HPVs (HR-HPV) are recognized a necessary 
but non-sufficient condition for the development of cervical cancer (zur Hausen, 1991; zur 
Hausen, 2009a; Zur Hausen, 2009b; Zur Hausen & Rosl, 1994). The majority of HPV 
infections are asymptomatic and are efficiently controlled by the host immune system, 
therefore, the outcome of HPV infection is variable (Woodman et al, 2007). Nowadays, 
screening programs of cervical cancer/lesions are based in cytology exam (Pap smear test) 
and HPV DNA detection. However, clinicians still demand for the identification of useful 
predictive/prognostic biomarkers for HPV infection and progression of lesions.  
Several studies have been performed to identify potential biomarkers for HPV infection 
outcome considering distinct events of HPV-related carcinogenesis and cellular 
modifications caused by HPV infection (Hwang & Shroyer, 2012). Recently, microRNAs 
(miRNAs), non-coding RNAs with proximally 18–25 nucleotides in length, have been 
proposed as optimal markers for cancer approach. miRNAs are responsible for modulate 
gene expression by binding to complementary segments present in the UTR of the mRNAs 
of protein coding genes leading to the suppression of translation and/or degradation of  
messenger RNA (mRNA) degradation (Melo & Esteller, 2011). miRNAs are thought to 
potentially target up to one-third of human coding genes managing cellular activity, 
including proliferation, differentiation and apoptosis (Malumbres, 2012; Melo & Esteller, 
2011). These molecules have been described as key regulators including cancer (Kong et al, 
2012). In fact, several studies have been addressing the impact of miRNAs in tumor 
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development either can act as oncogenes or tumor suppressor genes depending on neoplasia 
and number of miRNAs involved in human cancer has been growing (Malumbres, 2012).  
Recent studies have suggested microRNAs as possible markers for the occurrence and 
development of the HPV-associated cancers, including cervical cancer (Pereira et al, 2010). 
Moreover, studies have been described several interactions between microRNAS and HPV 
oncoproteins. Specific microRNAs have been located in cancer-related genomic regions, 
which include fragile sites at or near HPV integration sites. Differences in tumor-specific 
microRNA signatures might be an important tool to distinguish different lesions of the cervix 
(He et al, 2007a; He et al, 2007b; Martinez et al, 2008).  
The aim of this study was to characterize the expression of miR-34a and miR-125b in 
different cervical lesions and cancer, including normal cervical epithelium with or without 
HPV infection and to evaluate its impact as predictive/prognostic biomarkers of cervical 
cancer and HPV infection. 
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SUBJECTS, MATERIALS, AND METHODS 
Study population  
The study was performed in exfoliated cervical cells collected from 110 inpatient women with 
median age of 39±12.2 years old at the Portuguese Institute of Oncology of Porto. All samples 
were submitted to cytological examination classified according to the Bethesda classification, 
and confirmed by histological evaluation by experimented pathologists from our institution. 
The population of the study is constituted by 49 women with normal cytologies, 26 with low-
grade intraepithelial squamous lesions (LSIL), 21 with high-grade intraepithelial squamous 
lesions (HSIL), 7 with carcinomas in situ (CIS) and 4 with invasive cervical carcinomas 
(ICC). 
  
Sample processing 
Samples were collected in ThinPrep
®
 tubes (Hologic, USA) and stored at room temperature 
prior processing: a 4mL aliquot was used for digene HC2 High-Risk HPV DNA Test 
(QIAGEN, Germany); and 1 mL was used for total nucleic acids extraction using High Pure 
Viral Nucleic Acid kit (Roche, Germany).  
 
HPV infection  
HPV infection was detected by digene HC2 High-Risk HPV DNA Test (QIAGEN, Germany) 
(HC2) at the Virology Service of IPO Porto as part of routine procedures. HC2 test detect 13 
high-risk HPV (HR-HPV) types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV 
infection was detected in 65.4% of all cervical specimens, with a prevalence of 40.8% (20/49) 
for normal cytology, 73.1% (19/26) for LSIL, 95.2% (20/21) for HSIL, 100% (7/7) for CIS 
and 100% (4/4) for ICC. 
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miRNA analysis   
miR-125b, miR-34a and miR-23a were analysed using two-step real-time PCR protocols 
using TaqMan MicroRNA Assays: has-miR-125b-5p_000449; has-miR-34a-5p_000426; has-
miR-23a-3p_000399, respectively (Applied Biosystems, Foster CA, USA). 
Reverse transcriptase reactions were performed using TaqMan MicroRNA Reverse 
Transcription Kit (PN 4366596; Applied Biosystems, Foster CA, USA) in a 15uL of total 
volume reaction mix with: 7uL of master mix containing 1x RT buffer, 1.0mM of total 
dNTPs, 50U MultiScribe Reverse Transcriptase Enzyme and 0.25U of RNase inhibitor; 3uL 
of RT primers (Applied Biosystems, Foster CA, USA); and 5uL of RNA sample. The 
amplification conditions were as following: annealing at 16ºC for 30 min, extension at 42 ºC 
for 52 min and RT inactivation at 85ºC for 10 min. All reverse transcriptase reactions 
included two no-template controls (as negative controls we used double distilled water 
replacing template RNA). 
qPCRs were performed in independent reactions on an Applied Biosystems 7300 Real Time 
PCR System (Applied Biosystems, Foster CA, USA) with a 20μl final volume mixture 
containing 1× TaqMan® Universal PCR Master Mix (Applied Biosystems, Foster City, 
California USA), 1x  MicroRNA Assay (Applied Biosystems, Foster City, California USA) 
and 2 uL cDNA (RT product). Thermal cycling conditions were: 10 min. at 95°C followed by 
45 cycles of 15 sec. at 95°C and 1 min. at 60°C.  All reactions were run in duplicate.  
 
Data analysis   
The endpoint of qPCR data is the threshold cycle (Ct). The Ct is defined as the fractional 
cycle number at which the fluorescence passes the fixed threshold. 
The relative quantification of miRNA expression was analyzed using Livak method (also 
known as 2
-ΔΔCt
 method). In this method, Cts from the target miRNAs (miR-125b and miR-
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34a) in both test and reference cases were adjusted in relation to the Ct of a normalizer 
miRNA (miR-23a) resulting in ΔCt. The reference group in this study was women with 
normal cytology and without HPV infection. The difference between the ΔCt of cases and 
ΔCt reference gives the ΔΔCt value, which is incorporated to determine the fold difference in 
expression. 
 
Statistical Analysis  
Statistical Analysis was performed using the computer software IBM
®
 SPSS
®
 (Statistical 
Package for Social Sciences) Statistics version 20.0 for Mac. All cytologyc groups were 
compared, whenever appropriate, by Student’s t-test, ANOVA and Chi-square (χ2) test. 
Results are considered significantly different when P<0.05. Receiver operating characteristic 
(ROC) curves were used to assess the predictability of cervical disease progression. 
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RESULTS   
qPCR analysis 
qPCR results are shown in Table I where we describe, for all groups, the mean Ct, standard 
deviation, Ct range and the Variation Coefficient (VC). Firstly, we observed that qPCR was 
able to detect both low and high quantities of the miRNAs (overall ranging from 24.53 to 
41.35). Additionally, the VC for all miRNAs was bellow 10%, which reveals that the 
variation of Ct within samples was very low. These data also show that the High Pure Viral 
Nucleic Acid kit (Roche, Germany) was able to extract efficiently miRNA from this type of 
samples and that it could be used efficiently for future analysis.  
 
miRNAs expression  
Expression of selected miRNAs was determined for all samples, grouped according to 
cytological result, and normalized with a control group of women with normal cytology and 
without HPV infection (Table II).  
Considering the results of miR-125b expression (Table II and Fig1) there are interesting data: 
firstly, we observed a two-fold (2.11 relative expression) increase among normal cases with 
HPV infection (p=0.038); then, and despite there is no statistical significance, we also found a 
decrease of miR-125b expression for LSIL or HSIL (0.75 and 0.78 relative expression, 
respectively); finally, the analysis revealed that miR-125b expression was significantly 
decreased in women with either CIS or ICC (0.33 and 0.23 relative expression, respectively). 
In contrast to miR-125b, no differences in miR-34a expression were observed for the majority 
of study groups (Table II and Fig2). Despite the increase of miR-34a expression (1.69 relative 
expression) among women with normal cervix and HPV-infected (p=0.049), miR-34a is 
almost stably expressed in LSIL, HSIL or CIS/ICC (1.01, 1.32 and 1.06 relative expression, 
respectively). Additionally, we observed that when considering the CIS and ICC isolated we 
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observed that it seemed to be significant differences in relative expression (0.75 and 0.78 
relative expression, respectively), although these were not statistically significant. 
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DISCUSSION 
In the late decade miRNAs have been described as possible biomarkers of cancer 
development by regulating cellular behavior. Actually, miRNAs expression and biological 
functions are highly influenced by cellular context, probably due to the differential expression 
of their target mRNAs (Malumbres, 2012). In fact, the miRNAs expression varies from tissue 
to tissue and several studies attested that they are differentially expressed in abnormal tissue 
when compared with normal adjacent tissues. Moreover, miRNAs are thought to be highly 
stable when compared with mRNA and therefore their detection is relatively easy and 
reproducible, therefore suggesting that miRNAs might be good candidates for biomarkers and 
diagnostic tools in oncology.  
Recent studies have been developed to identify proof-valuable biomarkers for HPV infection 
outcome considering the cellular modifications caused by HPV infection and the cascade of 
distinct events of HPV carcinogenesis (Hwang & Shroyer, 2012). Literature have shown 
differential miRNA expression in cervical lesions and cancer tissues and also revealed 
potential interactions of miRNAs in HPV-associated carcinogenesis (Pereira et al, 2010). In 
our study, we investigated the expression of two miRNAs (miR-125b and miR-34a) that have 
been described as interacting in crucial steps of cervical cancer development. 
Our study is the first using qRT-PCR methodology to evaluate the expression of miRNAs in 
exfoliated cervical cells with high sensitivity and specificity. Nevertheless, we are aware that 
our study has limited number of samples mainly in CIS/ICC group and therefore it would be 
useful to develop further studies with increased number of samples. Moreover, the results 
could be significantly confirmed if we could access the biopsy sample of each patient and 
additionally improve the study with p53 expression either in biopsy or cytological samples. 
miR-125b has been described as involved in different cellular processes such as inflammation, 
cell proliferation and cell cycle regulation and therefore its action can be either as oncogene or 
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tumor suppressor depending on cell type (Jia et al, 2012; Le et al, 2009; Tili et al, 2008; 
Zhang et al, 2011). Our results start by demonstrating that miR-125b expression is increased 
in normal cervix infected by HPV, while the relative expression seems to decrease as lesions 
progress (Table II). According to literature, an increased expression of miR-125b shortly after 
HPV infection can be explained by interaction with viral proteins (Nicolete et al, 2012; 
Witwer et al, 2012). In fact, a recent study reveals that there is a strong homology between 
miR-125b and the HPV-L2 and therefore it is expected an increased expression of miR-125b 
shortly after viral infection as response to HPV proliferative with expression of HPV-L2 
(Nuovo et al, 2010). Additionally, Nuovo and colleagues showed that after persistent 
infection, HPV-L2 can induce inactivation of mir-125b and this event seems to be associated 
with cytological changes of the koilocytes (Nuovo et al, 2010). Literature also refers that 
since miR-125b is a negative regulator of p53 (Le et al, 2009; Zhou et al, 2010), its 
expression would allow a more effective suppression of p53-pathways and therefore 
contribute to abnormal transformation of infected cells (Sousa et al, 2007; Woodman et al, 
2007). 
miR-34a activity is considered as tumor suppressor and has been reported as down-regulated 
in several cancers (Hermeking, 2012). This miRNA is implicated in the p53-network and has 
been described as direct target of p53: when p53 is activated it induces the transcription of 
miR-34a which is able to target several molecules involved in cellular transformation and 
carcinogenesis (Bommer et al, 2007; Chang et al, 2007; Corney et al, 2007; He et al, 2007a; 
He et al, 2007b; Hermeking, 2012). Theoretically, in HPV-associated carcinogenesis, the 
expression of HPV-E6 will down-regulate the expression of miR-34a by targeting p53 to 
degradation thought the ubiquitin-proteasome system (Hermeking, 2012; Li et al, 2010; Sousa 
et al, 2007; Sousa et al, 2011). Therefore, it is expected that miR-34a deregulation occur after 
HPV infection, probably after viral genome integration into host’s genome. Li and colleagues 
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reported that inhibition of miR-34a expression is observed in precancerous lesions and 
probably represents an early-onset event in cervical cancer development (Hermeking, 2012; 
Li et al, 2010). In fact, several studies have been showed that levels of expression of miR-34a 
are significantly reduced in both cancer tissues and cervical cell lines, compared with normal 
tissues (Li et al, 2010; Wang et al, 2009). Although we have found an initial increase of miR-
34a expression in normal cells infected by HPV, we did not observe significant differences in 
relative expression when considering LSIL, HSIL or CIS/ICC. The increase of miR-34a 
expression in HPV infected cells is probably explained by the activation of cellular repair 
mechanisms after viral infection that would activate p53-pathways and therefore induce miR-
34a expression. Nevertheless, results do not corroborate prior reports on miR-34a and cervical 
cancer and therefore we conclude that miR-34a expression profile in HPV infection and 
cervical lesions/cancer remains unclear.  
In conclusion, our study revealed that miR-125b expression is up-regulated in normal tissues 
after HPV infection, and decreases significantly as cervical lesions progress to invasive 
carcinoma. In fact ROC revealed significant sensitivity and specificity for CIS/ICC diagnosis 
(data not shown). These results suggest that miR-125b could probably be used as useful tool 
for cervical lesions diagnosis/prognosis using a non-invasive approach, though this 
observation needs to be complemented with further studies.  
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Table I: qPCR data analysis 
 miR125b  miR34a  miR23a  
 Mean Ct ± sd (range) VC Mean Ct ± sd (range) VC Mean Ct ± sd (range) VC 
No Lesion (no HPV) (n=29) 28.43 ± 2.48 (24.60 – 36.51) 0.09 34.14 ± 1.82 (30.07 – 37.95) 0.05 34.94 ± 1.72 (32.53 – 39.49) 0.05 
No Lesion (HPV+) (n=20) 28.06 ± 2.20 (24.53 – 32.07) 0.08 34.09 ± 1.58 (31.18 – 37.10) 0.04 35.65 ± 2.58 (32.30 – 41.35) 0.07 
LSIL (n=28) 29.34 ± 2.12 (25.55 – 34.34) 0.07 34.60 ± 1.71 (31.49 – 38.15) 0.05 35.42 ± 2.04 (31.85 – 40.97) 0.06 
HSIL (n=21) 29.06 ± 1.81 (26.48 – 32.71) 0.06 34.01 ± 1.22 (32.29 – 36.89) 0.04 35.21 ± 1.73 (32.32 – 39.13) 0.05 
CIS/ICC (n=12) 29.39 ± 2.67 (26.08 – 33.85) 0.09 33.22 ± 1.89 (28.67 – 35.86) 0.06 34.10 ± 1.29 (31.79 – 36.92) 0.04 
     CIS (n=7) 29.48 ± 2.66 (26.20 – 33.85) 0.09 34.28 ± 1.03 (32.54 – 35.86) 0.03 34.40 ± 1.65 (31.79 – 36.92) 0.05 
     ICC (n=5) 29.27 ± 2.99 (26.08 – 33.11) 0.10 31.73 ± 1.87 (28.67 – 33.34) 0.06 33.68 ± 0.35 (33.33 – 34.33) 0.01 
Ct, cycle threshold; Sd, Standard Deviation; VC, variation coefficient; LSIL, Low-grade intraepithelial lesions; HSIL, High-grade intraepithelial lesions; CIS, carcinoma in 
situ, ICC, Invasive cervical carcinoma. 
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Table II: Expression profile data for miR-125b and miR-34a in cervical lesions 
 miR125b  miR34a  
 ΔCt ± sd (range) 2-ΔΔCt t-test ΔCt ± sd (range) 2-ΔΔCt t-test 
No Lesion (no HPV) (n=29) -6.51 ± 1.73 (-10.59 – -0.77) Reference  -0.80 ± 1.16 (-2.82 – 1.67) Reference  
No Lesion (HPV+) (n=20) -7.59 ± 1.77 (-10.79 – -4.28) 2.11 0.038 -1.56 ± 1.47 (-4.30 – 0.54) 1.69 0.049 
LSIL (n=28) -6.09 ± 1.44 (-9.86 – -3.94) 0.75 0.320 -0.82 ± 1.81 (-4.26 – 2.45) 1.01 0.955 
HSIL (n=21) -6.15 ± 1.83 (-9.10 – -2.30) 0.78 0.481 -1.20 ± 1.74 (-5.32 – 1.65) 1.32 0.335 
CIS/ICC (n=12) -4.71 ± 2.22 (-8.24 – -1.13) 0.29 0.008 -0.88 ± 1.62 (-4.87 – 0.75) 1.06 0.156 
     CIS (n=7) -4.92 ± 2.00 (-8.24 – -3.07) 0.33 0.042 -0.12 ± 0.84 (-1.47 – 0.75) 0.62 0.074 
     ICC (n=5) -4.41 ± 2.70 (-7.46 – -1.13) 0.23 0.028 -1.94 ± 1.92 (-4.87 – -0.26) 2.20 0.857 
Ct, cycle threshold; Sd, Standard Deviation; LSIL, Low-grade intraepithelial lesions; HSIL, High-grade intraepithelial lesions; CIS, carcinoma in situ, ICC, Invasive cervical 
carcinoma.  
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Figure 1: Expression profile of miR-34a in different cervical lesions 
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Figure 2: Expression profile of miR-125b in different Cervical lesions 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENERAL DISCUSSION AND 
 FUTURE STUDIES 
 
GENERAL DISCUSSION AND FUTURE STUDIES 
 
Genetic Markers of HPV Infection and Cervical Cancer: Clinical Utility | 89 
GENERAL DISCUSSION AND FUTURE STUDIES 
 
Clinical and subclinical HPV infections are the most common sexually transmitted infections 
in the world and this infection has been established as the cause of genital warts, squamous 
intraepithelial lesions of the cervix and other types of anogenital lesions [zur Hausen, 1991; 
zur Hausen, 2009a; Zur Hausen, 2009b; Zur Hausen and Rosl, 1994]. However, only certain 
types of HPVs are able to induce cervical cancer development  In fact, HPV can be classified 
into high-risk types, which are frequently associated with the development of epithelial 
lesions of the cervix, and low-risk types, which are found mainly in genital warts and benign 
lesion [de Villiers et al., 2004; Munoz et al., 2006; Nobre et al., 2008]. 
Portugal has a relatively high incidence rate for cervical cancer and one of the highest 
mortality rates in the developed countries, mainly due to a limited screening program for 
cervical cancer [Jemal et al, 2011]. Recently, a vaccination program against HPV infection 
was included in the National Program of Vaccination and therefore it is expected a decrease in 
the prevalence of HPV infection among young. 
Distribution of HPV genotypes has changed in population in worldwide, hence, and 
epidemiological studies regarding prevalence of HPV types should to be performed to 
characterize their frequency. Our results showed that HPV16 is the most frequent types 
among Portuguese women followed by HPV58, 39, 53 and 66. Surprising, HPV18 proved to 
be a rare genotype in our population. Although the distribution of HPV genotypes have been 
evaluated in a small number of women, our data should be included in future approaches, 
mainly in the decision of future vaccination programs in Portugal.  
Integration of viral genome into host´s genome has been considered a crucial event in HPV-
associated carcinogenesis and some authors have been proposed that physical status of HPV 
genome should be a considered as prognostic biomarker of  cervical lesions [Hwang et al, 
2012]. Different methodologies have been described to determine physical status of HPV 
genotypes and therefore the variability could be considered a potential disadvantage. In our 
study we determined the viral physical status only in HPV16 positive cases (the most 
prevalent HPV type) and the most significant data was that it was possible to detect integrated 
forms in early lesions of the cervix. Hence, further studies are required, preferably, cohort 
studies, to follow-up normal and LSIL cases that are infected with HPV in integrated state and 
evaluate their progression.  
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MicroRNAs play a fundamental role in human biology and recent studies have suggested 
these molecules as possible markers for the occurrence and development of the HPV-
associated cancers [Melo and Esteller, 2011; Martinez et al, 2008]. Differences in tumor-
specific microRNA signatures have been proposed to distinguish different lesions, although 
conclusions are still unclear. Several studies have been performed determining the expression 
of different miRNAs in cervical tissues and evaluating their value as biomarkers. We focused 
this study in two miRNAs (miR-125b and miR-34a) that play a key role in distinct cellular 
processes. Scientific literature reveals that HPV proteins seem to interact with both miR-34a 
and miR-125b changing its expression and promoting viral infection and cervical cancer 
development [Hermeking, 2012; Li et al., 2010; Tili et al., 2008; Le et al, 2009 Zhang et al., 
2011]. 
miR-34a has been included  as active member of the p53-network, mainly because it was 
described as direct target of p53. The activation of p53 leads to miR-34a transcription and 
consequently to the suppression several molecules involved in cellular transformation and 
carcinogenesis [Bommer et al., 2007; Chang et al., 2007; Corney et al., 2007; He et al., 
2007a; He et al., 2007b]. 
Our results regarding miR-34a expression in cervical cells revealed an increase expression in 
normal cervix when infected by HPV; however, no significant difference was observed for 
LSIL, HSIL or CIS/ICC. This is the first study to indicate that levels of miR-34a remain 
constant during cervical carcinogenesis. According to the literature, it was expected that after 
HPV infection the expression of HPV-E6 would target p53 to degradation and therefore miR-
34a levels should be decreased. Thus, we think that expression of p53 should be evaluated to 
correlate with miR-34a levels and understand if there are other mechanism that controls miR-
34a expression.  
Considering miR-125b, our study revealed that its expression is up-regulated in normal tissues 
after HPV infection, and decreases significantly as cervical lesions progress to invasive 
carcinoma. These results are in agreement with a previous in vitro study that described an 
interaction between miR-125b and HPV-L2 a possible role on the initial steps of cervical 
carcinogenesis, including inflammation and immune response against HPV infection. Our 
results suggest that miR-125b could probably be used as useful tool for cervical lesions 
diagnosis/prognosis using a non-invasive approach, though this observation needs to be 
complemented with further studies.  
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The role of microRNAs in cervical cancer development is still unclear and studies reporting 
expression of microRNAs in cervical tissues are needed to clarify this mechanism. A better 
understanding of the microRNAs in cervical cancer may not only reveal novel pathogenic 
mechanism of HPV but also identity potential targets for cervical cancer therapy. 
Additionally, specific miRNA expression profile would be useful as a biomarker for cancer 
and viral infection. 
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